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Abstract The product of the growth arrest specific gene, gas1,
is a membrane-associated protein which activates a p53-
dependent growth suppression signalling pathway. We have
shown that Gas1 is linked to the plasma membrane through a
glycosyl-phosphatidylinositol (GPI) anchor. Several GPI-an-
chored protein have been identified as part of receptor complexes
either as co-receptors or as membrane bound ligands. In this
report, we characterize the Gas1 domains required for its growth
suppression function and demonstrate the dispensability of Gas1
GPI anchor. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Gas1 is a membrane-associated protein which is highly ex-
pressed at growth arrest and down-regulated under prolifer-
ative conditions. We have previously shown that this protein
is able to interfere with cell proliferation when ectopically
expressed in asynchronously growing cells or during the Go
to S transition [1,2]. We have also shown that the inhibitory
e¡ect of Gas1 depends on the presence of p53 [3]. In partic-
ular the proline-rich domain of p53 [4] and not its transacti-
vation function is required for the Gas1-induced growth sup-
pression [3,4]. Since Gas1 is localized on the plasma
membrane, it might be involved in the transduction of an
inhibitory signal, at growth arrest, leading to p53.
We have demonstrated that Gas1 is tethered to the plasma
membrane through a glycosyl-phosphatidylinositol (GPI) an-
chor [5]. A wide variety of proteins are attached to the cell
surface by a GPI anchor. Such proteins include hydrolytic
enzymes, cell adhesion molecules, receptors and cell surface
antigens [6]. Several GPI-anchored protein have been identi-
¢ed as part of a receptor complex either as co-receptors [7] or
as membrane bound ligands [8].
As it is the case for other GPI-anchored proteins [7], in this
work we have demonstrated that the GPI anchor is dispens-
able for the growth inhibitory activity of Gas1. Moreover, by
the use of chimeric constructs between Gas1 and the GPI-
anchored human placental alkaline phosphatase (hPLAP),
we have de¢ned the minimal region endowed with the Gas1
growth arrest activity.
2. Materials and methods
2.1. Plasmids
Most of the constructs used in this work were subcloned in the
pGDSV7S vector [9].
pGDSV7S-gas1Met42 is described in Stebel et al. [5].
pGDSV7S-hSEAP (human SEcreted Alkaline Phosphatase) encodes
a secreted form of PLacental Alkaline Phosphatase (hPLAP), ending
at the amino acid (aa) 489 and therefore lacking the GPI consensus
sequence.
pGDSV7S-Gas1/hSEAP encodes a chimera containing Gas1 from
aa 42 to 366 and hSEAP from aa 1 to 489.
pGDSV7S-Gas1-6His encodes a soluble form of Gas1, having sub-
stituted the GPI consensus sequence from aa 367 onwards with a six
histidine tag.
pGas1-Fc encodes a Gas1 protein from aa 42 to 367 in fusion with
the human Fc domain. To construct the chimera, a PCR fragment of
Gas1 was ampli¢ed and subcloned in the HindIII^BamHI sites of the
pIg vector (RpD Systems).
pMuc-Fc is a fusion construct provided by RpD Systems contain-
ing the MUC18 glycoprotein [10] in fusion with the human Fc do-
main.
pGDSV7S-hPLAP encodes the full-length hPLAP, derived from
subcloning of the EcoRI fragment of pSVT7hPLAP [11].
pGDSV7S-Gas1-Sma/hPLAP contains gas1 up to the SmaI site and
the hPLAP; it encodes a chimera containing Gas1 from aa 42 to 193
followed by hPLAP from aa 55 to the end.
pGDSV7S-Gas1-Hind/hPLAP contains gas1 up to the HindIII site
and encodes a chimera containing Gas1 from aa 42 to 229 followed by
hPLAP from aa 26 to the end.
pGDSV7S-hPLAP/Hind-Gas1 contains the sequence of hPLAP de-
leted of the GPI addition signal and gas1 from the HindIII site to the
end; it encodes a chimera containing hPLAP from aa 22 to 383
followed by Gas1 from aa 230 to the end.
pGDSV7S-hPLAP/Gas1 Sma-Hind contains a fragment of Gas1
comprised between the SmaI and HindIII sites (corresponding to aa
182^234) inserted at the PstI site of hPLAP.
2.2. Cell culture and transfections
NIH3T3 and COS7 cells were grown as described [2]. Transfection
of COS7 cells was performed with 2 Wg of DNA/35 mm diameter plate
or 15 Wg DNA/10 cm diameter plate, using the DEAE-dextran pro-
cedure as described [12].
2.3. [35S]Met cell labelling procedure and immunoprecipitation
2 days after transfection, COS7 cells were starved for methionine
for 1 h prior to addition of 150 WCi/ml of [35S]methionine (Amer-
sham). Cells were labelled for 5 h, lysed and processed as described
[5]. The di¡erent protein products were immunoprecipitated by using
a⁄nity-puri¢ed anti-Gas1 antibodies. For immunoprecipitation of
hPLAP and hSEAP, commercial anti-hPLAP antibodies (Dako)
were used. Gas1-Fc and Muc-Fc were pulled-down from cell super-
natants using protein A-Sepharose (Pharmacia).
2.4. Gas1-Fc production and inhibition assay
Gas1-Fc and Muc-Fc plasmids were transfected, as described, into
COS7 cells. 24 h after transfection, the medium was changed to 0.5%
fetal calf serum to reduce cell growth while allowing accumulation of
the secreted protein. Cells were incubated for a further 48 h; medium
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was collected and centrifuged at 2500Ug for 10 min to eliminate the
cellular debris. To quantify the secreted recombinant protein, 1 Wl of
di¡erent dilutions of each conditioned medium were spotted on nitro-
cellulose together with a standard concentration of human IgG. After
air drying, the membrane was blocked with 3% bovine serum albumin
(BSA) in phosphate-bu¡ered saline (PBS) and incubated with protein
A-peroxidase (Sigma) (1:1000 in PBS^3% BSA) for 1 h at room tem-
perature. Enzyme activity was detected using the enhanced chemilu-
minescence method (Amersham, UK). For the inhibition assays,
NIH3T3 cells were plated on a coverslip in 35 mm Petri dishes as
described [2]. After 24 h, 500 Wl of Gas1-Fc transfected COS7 cells
medium, containing 3 ng/Wl of recombinant protein, was directly
added to 1.5 ml of culture medium of growing NIH3T3 cells (750
ng/ml Gas1-Fc ¢nal concentration). As a control, medium from
Muc-Fc-transfected COS cells, containing the same concentration of
recombinant protein, and medium from mock-transfected cells were
used. 18 h later, 50 WM bromo-deoxy-uridine (BrdU) was added and
incubation was continued for a further 6 h. Cells were then ¢xed and
processed for immuno£uorescence. Incorporation of BrdU was re-
vealed by anti-BrdU monoclonal antibody (IgG2a) (Amersham) fol-
lowed by TRITC-conjugated goat anti-mouse IgG2a antibody (South-
ern Biotechnology). For visualizing the nuclei, the cells were
incubated with 2 Wg/ml Hoechst 33342 (Fluka) in PBS. Relative
amounts of BrdU positive cells (indicative of S phase) in the sample
treated with Gas1-Fc or with Muc-Fc were compared with that of
untreated cells.
2.5. Microinjection and biological assays
All microinjection experiments were performed using an automated
injection system, AIS (Zeiss, Oberkochen, Germany), as described [2].
50 ng/Wl of cDNA was microinjected into the nuclei of asynchro-
nously growing NIH3T3 cells. After injection, cells were incubated
for 18 h, then 50 WM BrdU was added and incubation was continued
for a further 6 h. Cells were then ¢xed and processed for immuno-
£uorescence as described [2,3]. Gas1 was revealed by a⁄nity-puri¢ed
QE 229 anti-Gas1 antibody [5] followed by FITC-conjugated goat
anti-rabbit IgG (Sigma). hPLAP was revealed by polyclonal antibod-
ies (Dako) followed by FITC-conjugated goat anti-rabbit IgG (Sig-
ma). Incorporation of BrdU was revealed as described above.
3. Results
3.1. The GPI anchor is dispensable for the growth arrest
activity of Gas1
In the accompanying paper [5], we have demonstrated that
Gas1 is a GPI-anchored protein. Among the several proteins
with diverse physiological functions that are tethered to the
surface of the cell by a GPI anchor, some are essential com-
ponents of receptor complexes [13,14], and in some cases the
presence of the soluble form of the co-receptor still allows the
transmembrane protein component to transduce the signal. In
order to elucidate whether Gas1 belongs to this category of
proteins, we wanted to assess whether the GPI anchor was
required for the Gas1 inhibitory activity.
Two constructs were generated in which the GPI consensus
sequence of Gas1 was replaced by either a six His tag (Gas1-
6His) or by the sequence of human secreted alkaline phospha-
tase (Gas1-SEAP) (Fig. 1A). Immunoprecipitation with anti-
Gas1 antibody of the culture medium of COS7 cells trans-
fected with either Gas1-6His or Gas1-SEAP expression vec-
tors con¢rmed that both proteins were e⁄ciently secreted
(Fig. 1B). Next, the same constructs were analyzed for their
ability to induce growth arrest in NIH3T3 ¢broblasts. Ectopic
expression of these constructs was performed by microinjec-
tion and its e¡ects on cell cycle were evaluated by measuring
the relative level of BrdU incorporation. As shown in Fig. 1C,
Gas1-6His and Gas1-SEAP exhibited a growth inhibitory ac-
tivity comparable to the full-length, GPI-anchored Gas1,
while hSEAP (negative control) had no e¡ect. To further con-
¢rm this result, another soluble construct was prepared in
which the Gas1 sequence was fused with the Fc region of
the human IgG (Gas1-Fc). The corresponding protein pro-
duced in COS7 cells was e⁄ciently secreted as shown by pro-
tein A-Sepharose pull-down of culture medium from radio-
labelled cells (Fig. 1D) or Western blot with anti-human
IgG antibodies (Fig. 1E). The growth arrest ability of this
soluble construct was tested by adding the medium of COS7
transfected cells to the culture medium of asynchronously
growing NIH3T3 ¢broblasts. As shown in Fig. 1F, the
Gas1-Fc fusion protein exogenously added to cells inhibited
S phase entry as e¡ectively as the other soluble forms of Gas1
expressed by microinjection (compare Fig. 1C with Fig. 1F).
Muc-Fc (negative control) had no e¡ect. These results dem-
onstrate that anchoring to the plasma membrane is not re-
quired for Gas1 to exert its growth inhibitory activity and that
the GPI moiety does not seem to participate in the signalling
cascade.
3.2. Mapping the functional region of Gas1
In order to determine the domains of the Gas1 protein
responsible for the growth inhibitory activity, a series of chi-
meras were constructed containing various fragments of gas1
fused to the hPLAP cDNA using either the GPI anchor con-
sensus sequence from hPLAP or from Gas1 (Fig. 2A). The
protein products of the chimeras were recognized both by the
anti-hPLAP antibody and by the anti-Gas1 antibody speci¢c
for the cloned regions, as assessed by immunoprecipitation
(Fig. 2B) and by immuno£uorescence microscopy (not
shown).
To test the ability of the Gas1/hPLAP chimeras to induce
growth arrest in NIH3T3 ¢broblasts, ectopic expression was
performed by microinjecting the individual expression plas-
mids and the e¡ect on cell cycle was evaluated by measuring
the level of BrdU incorporation. As shown in Fig. 2C, the
Gas1-Hind/hPLAP hybrid consisting of the N-terminal half of
Gas1 up to aa 229 showed a signi¢cant inhibitory e¡ect which
Fig. 1. Growth inhibitory analysis of soluble Gas1 constructs. A: Scheme of the chimeras. The numbers in the upper part of each construct re-
fer to the aa sequence of Gas1 as predicted from the open reading frame (ORF); the numbers of the aa of the human Fc region are not re-
ported. B: Immunoprecipitation of the soluble products of the constructs Gas1-6His and Gas1-SEAP from the culture medium of transfected,
[35S]Met-labelled COS7 cells. C: Relative inhibition of BrdU incorporation by expression of the Gas1 GPI minus constructs (Gas1-hSEAP and
Gas1-6His) compared to the Gas1 GPI-linked (Gas1-Met42). Relative inhibition of DNA synthesis was calculated as follows: % relative inhibi-
tion = [% BrdU positive cells (uninjected)3% BrdU positive cells (Gas1/6His positive)/% BrdU positive cells (uninjected)]U100. The mean of
three independent experiments with at least 300 over-expressing scored cells is shown. D: The conditioned medium from the Gas1-Fc- and
Muc-Fc-transfected and [35S]Met-labelled COS7 cells was subjected to pull-down with protein A-Sepharose, separated on SDS^PAGE and the
proteins were visualized by autoradiography. E: The conditioned medium from Gas1-Fc and Muc-Fc-transfected COS7 pulled-down with pro-
tein A-Sepharose, separated on SDS^PAGE and immunodecorated with anti-human Fc antibody. F: Relative inhibition of BrdU incorporation
by conditioned medium of Gas1-Fc- or Muc-Fc- (negative control) transfected COS cells. Inhibition was calculated as relative to the BrdU in-
corporation percentage in untreated cells.
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was comparable to the ‘wild type’ Gas1. In contrast, the Gas1
C-terminal moiety from aa 230 to aa 384 (hPLAP/HindGas1)
had no signi¢cant e¡ect, similar to the negative control
hPLAP.
In order to further delineate the inhibitory region, two oth-
er chimeras were constructed: Gas1-Sma/hPLAP which con-
tains the sequence encoding Gas1 up to aa 193, and which
contains the sequence encoding Gas1 from aa 182 to 234,
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both inserted into the hPLAP backbone (Fig. 2A). When
similarly over-expressed in growing NIH3T3 cells, these chi-
meras did not show an inhibitory activity comparable to the
full-length Gas1, although hPLAP/Gas1Sma-Hind retained
signi¢cant activity. These results indicate that the portion of
Gas1 from aa 182 to aa 234 is required, although not su⁄-
cient, to confer inhibitory function. This suggested that either
the surrounding aa in the Gas1 sequence were important to
provide the conformation required for Gas1 function or that
another domain in the amino-terminal region although inef-
fective alone, was required to confer a full inhibitory activity
to Gas1. To verify the latter possibility, the two constructs
Gas1-Sma/hPLAP and the hPLAP/Gas1Sma-Hind were co-
microinjected. The percentage of inhibition obtained did not
di¡er from that of the single construct, thus indicating that
the two chimeras are not able to cooperate (not shown). We
can therefore conclude that the most critical domain resides
between aa 182 and aa 234 but that this domain is in£uenced
by the surrounding aa sequence to exert growth suppressing
activity e⁄ciently.
Fig. 2. Growth inhibitory analysis of Gas1-hPLAP constructs in NIH3T3 ¢broblasts. A: Scheme of the chimeras. The numbers in the upper
part of each construct refer to the aa sequence of Gas1 as predicted from the ORF; those in the lower part to the aa sequence of hPLAP. As
for hPLAP, the numeration starts from 322 corresponding to the ¢rst translated aa which however belongs to the signal peptide and is cleaved
o¡ the mature protein. In each construct, the signal peptide traces to the protein at the amino-terminus, while the GPI consensus sequence
traces to the protein at the carboxy-terminus. B: Immunoprecipitation of the di¡erent anchored constructs expressed in transfected, [35S]Met-la-
belled COS cells. C: Relative inhibition of BrdU incorporation after expression of Gas1 or the di¡erent Gas1-hPLAP mutants. Inhibition was
calculated as in Fig. 1C. The mean of three independent experiments with at least 300 over-expressing scored cells is shown.
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4. Discussion
Gas1 exerts growth suppression activity in various cell
types. We have demonstrated, in the accompanying paper
[5], that the Gas1 protein is associated to the plasma mem-
brane via a GPI anchor. Several GPI proteins have been iden-
ti¢ed as components of receptor complexes. In the case of
GDNF signalling, a family of soluble factors ^ glial cell-de-
rived neurotrophic factor (GDNF) [15], neurturin (NTN)
[16,17], persephin [18] and artemin [19] ^ has been character-
ized for supporting survival in di¡erent populations of neu-
rons. GDNF and NTN interact on the plasma membrane
with their speci¢c GPI-linked co-receptor, respectively called
GFRK-1 and GFRK-2. Once formed, the complex ligand^co-
receptor binds to the transmembrane protein kinase Ret
which is responsible for transducing the signal. Therefore
the signalling protein, Ret, is shared while the GPI-linked
co-receptor determines ligand speci¢city [15^18,20]. Another
example is that of lipopolysacharide (LPS)-induced cellular
signalling in myeloid cells. The response to LPS requires a
plasma protein (LPS-binding protein, LBP) that forms a com-
plex with LPS, which then is able to interact with the GPI-
linked CD14 receptor. Most importantly, the soluble form of
CD14 has been shown to be su⁄cient to mediate LPS-induced
signalling [21], thus prompting the search for the supposed
transmembrane signalling receptor. This has led to the discov-
ery of the Toll-like receptor 2 with which the complex LPS^
LBP^CD14 interacts [14]. We therefore wished to verify
whether this could be true also in the case of Gas1. By the
use of di¡erent soluble constructs, we have demonstrated the
dispensability of the GPI anchor. The use of Gas1-Fc exoge-
nously added to the cells was particularly instructive since it
clearly demonstrated that Gas1 can induce growth arrest from
outside, excluding the possibility that the soluble constructs
expressed by microinjection could function along the secretion
pathway.
Moreover, by the use of chimeric constructs, we were able
to restrict the ‘minimal’ functional domain of Gas1 to the
region comprised between the Sma^Hind sites (aa 182^234).
This domain still retains some inhibitory activity and anti-
bodies raised against this epitope are able to block Gas1
function (data not shown).
Altogether, the results presented support the hypothesis of
the existence of a complex, containing Gas1, involved in the
transduction of a growth suppression signal during Go. Fur-
ther investigation is required to try and identify the other
component(s) of this complex.
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